Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The pathogenesis of osteoporosis in chronic liver disease and post-liver transplantation is complex and heterogeneous. The development of hepatic osteodystrophy may be related to both increased bone resorption and decreased bone formation. Available medical treatments can be broadly classified into antiresorptive and bone-stimulating agents. Most published studies on the treatment of osteoporosis in patients with liver disease have used the commonly prescribed antiosteoporosis drugs approved for postmenopausal osteoporosis. These studies have included a small number of subjects and used bone mineral density (BMD) changes rather than fracture occurrence as an endpoint because of the short follow-up. Although the increases in BMD are promising, no intervention is proven to have antifracture efficacy in hepatic osteodystrophy. The natural history of bone disease following Liver transplantation has not been fully investigated, although studies suggest that bone mineral loss is transient and generally reverses within a year following transplantation. The approach to treatment in liver transplant recipients should be targeted at preventing the early bone loss without interfering with the later recovery. Based on the available data, no single available agent can be considered as first-line therapy. In our opinion, the best treatment approach involves the elucidation of modifiable risk factors and the selection of agents targeted at the underlying derangement.

Original languageEnglish (US)
Pages (from-to)456-463
Number of pages8
JournalCurrent Treatment Options in Gastroenterology
Volume9
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

Osteoporosis
Liver Diseases
Chronic Disease
Liver
Bone and Bones
Liver Transplantation
Bone Density
Therapeutics
Postmenopausal Osteoporosis
Bone Diseases
Bone Resorption
Osteogenesis
Minerals
Transplantation
Transplant Recipients
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{57ba2d5636974fe5b9d9c65c471a83fa,
title = "Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients",
abstract = "The pathogenesis of osteoporosis in chronic liver disease and post-liver transplantation is complex and heterogeneous. The development of hepatic osteodystrophy may be related to both increased bone resorption and decreased bone formation. Available medical treatments can be broadly classified into antiresorptive and bone-stimulating agents. Most published studies on the treatment of osteoporosis in patients with liver disease have used the commonly prescribed antiosteoporosis drugs approved for postmenopausal osteoporosis. These studies have included a small number of subjects and used bone mineral density (BMD) changes rather than fracture occurrence as an endpoint because of the short follow-up. Although the increases in BMD are promising, no intervention is proven to have antifracture efficacy in hepatic osteodystrophy. The natural history of bone disease following Liver transplantation has not been fully investigated, although studies suggest that bone mineral loss is transient and generally reverses within a year following transplantation. The approach to treatment in liver transplant recipients should be targeted at preventing the early bone loss without interfering with the later recovery. Based on the available data, no single available agent can be considered as first-line therapy. In our opinion, the best treatment approach involves the elucidation of modifiable risk factors and the selection of agents targeted at the underlying derangement.",
author = "Maalouf, {Naim M.} and Khashayar Sakhaee",
year = "2006",
month = "12",
doi = "10.1007/s11938-006-0002-y",
language = "English (US)",
volume = "9",
pages = "456--463",
journal = "Current Treatment Options in Gastroenterology",
issn = "1092-8472",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients

AU - Maalouf, Naim M.

AU - Sakhaee, Khashayar

PY - 2006/12

Y1 - 2006/12

N2 - The pathogenesis of osteoporosis in chronic liver disease and post-liver transplantation is complex and heterogeneous. The development of hepatic osteodystrophy may be related to both increased bone resorption and decreased bone formation. Available medical treatments can be broadly classified into antiresorptive and bone-stimulating agents. Most published studies on the treatment of osteoporosis in patients with liver disease have used the commonly prescribed antiosteoporosis drugs approved for postmenopausal osteoporosis. These studies have included a small number of subjects and used bone mineral density (BMD) changes rather than fracture occurrence as an endpoint because of the short follow-up. Although the increases in BMD are promising, no intervention is proven to have antifracture efficacy in hepatic osteodystrophy. The natural history of bone disease following Liver transplantation has not been fully investigated, although studies suggest that bone mineral loss is transient and generally reverses within a year following transplantation. The approach to treatment in liver transplant recipients should be targeted at preventing the early bone loss without interfering with the later recovery. Based on the available data, no single available agent can be considered as first-line therapy. In our opinion, the best treatment approach involves the elucidation of modifiable risk factors and the selection of agents targeted at the underlying derangement.

AB - The pathogenesis of osteoporosis in chronic liver disease and post-liver transplantation is complex and heterogeneous. The development of hepatic osteodystrophy may be related to both increased bone resorption and decreased bone formation. Available medical treatments can be broadly classified into antiresorptive and bone-stimulating agents. Most published studies on the treatment of osteoporosis in patients with liver disease have used the commonly prescribed antiosteoporosis drugs approved for postmenopausal osteoporosis. These studies have included a small number of subjects and used bone mineral density (BMD) changes rather than fracture occurrence as an endpoint because of the short follow-up. Although the increases in BMD are promising, no intervention is proven to have antifracture efficacy in hepatic osteodystrophy. The natural history of bone disease following Liver transplantation has not been fully investigated, although studies suggest that bone mineral loss is transient and generally reverses within a year following transplantation. The approach to treatment in liver transplant recipients should be targeted at preventing the early bone loss without interfering with the later recovery. Based on the available data, no single available agent can be considered as first-line therapy. In our opinion, the best treatment approach involves the elucidation of modifiable risk factors and the selection of agents targeted at the underlying derangement.

UR - http://www.scopus.com/inward/record.url?scp=33751329354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751329354&partnerID=8YFLogxK

U2 - 10.1007/s11938-006-0002-y

DO - 10.1007/s11938-006-0002-y

M3 - Article

C2 - 17081479

AN - SCOPUS:33751329354

VL - 9

SP - 456

EP - 463

JO - Current Treatment Options in Gastroenterology

JF - Current Treatment Options in Gastroenterology

SN - 1092-8472

IS - 6

ER -